Jason D. Christie

faculty photo
Robert M. Kotloff/Nancy P. Blumenthal Professor for Advanced Lung Disease
Member, Biomedical Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Department of Biostatistics and Epidemiology
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania
Adjunct Investigator, Institute for Environmental Medicine, Perelman School of Medicine at the University of Pennsylvania
Director, Center for Translational Lung Biology, Perelman School of Medicine at the University of Pennsylvania
Program Leader for Transplantation, Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania
Chief, Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania
Department: Medicine

Contact information
Division of Pulmonary and Critical Care Medicine
Hospital of the University of Pennsylvania
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania School of Medicine
423 Guardian Drive
221 Blockley Hall
Philadelphia, PA 19104
Office: (215) 573-3209
Fax: (215) 573-0198
Graduate Group Affiliations
Education:
Sc.B. (Chemistry)
Brown University, 1989.
M.D. (Medicine)
Columbia University, 1993.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, 2002.
Permanent link
 

Description of Research Expertise

Dr. Christie's career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury in the transplant and non-transplant human populations. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.

Dr. Christie is the founder of the lung transplant outcomes group (LTOG), which is a multicentered cohort study the etiology and pathogenesis of acute lung injury following lung transplantation (termed primary graft dysfunction). Active LTOG research themes focus on the mechanisms of clinical factors that elevate PGD risk, including donor smoke exposure, recipient obesity and body composition, pulmonary hypertension, alterations in lung microbiome, and autoimmunity to lung collagens. His multidisciplinary lung transplant research focuses on genetics, innate immunity, regulatory T-cells, innate lymphoid cell (ILC) populations in the lung, ischemia reperfusion injury, inflammation, and autoimmunity.

Description of Itmat Expertise

His career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury in the transplant and non-transplant human populations. Through leadership of the Center for Translational Lung Biology, Dr. Christie brings together clinicians, bench scientists, epidemiologists, and statisticians to build multidisciplinary research teams. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.

Dr. Christie is the founder of the lung transplant outcomes group (LTOG), which is a multicentered cohort study the etiology and pathogenesis of acute lung injury following lung transplantation (termed primary graft dysfunction). Active LTOG research themes focus on the mechanisms of clinical factors that elevate PGD risk, including donor smoke exposure, recipient obesity and body composition, pulmonary hypertension, alterations in lung microbiome, and autoimmunity to lung collagens.

Selected Publications

Chreiman KM, Dumas RP, Seamon MJ, Kim PK, Reilly PM, Kaplan LJ, Christie JD, Holena DN.: The intraosseous have it: A prospective observational study of vascular access success rates in patients in extremis using video review. J Trauma Acute Care Surg April 2018.

Singer JP, Diamond JM, Anderson MR, Katz PP, Covinsky K, Oyster M, Blue T, Soong A, Kalman L, Shrestha P, Arcasoy SM, Greenland JR, Shah L, Kukreja J, Blumenthal NP, Easthausen I, Golden JA, McBurnie A, Cantu E, Sonett J, Hays S, Robbins H, Raza K, Bacchetta M, Shah RJ, D'Ovidio F, Venado A, Christie JD, Lederer DJ.: Frailty phenotypes and mortality after lung transplantation: a prospective cohort study. Am J Transplant April 2018 Notes: [Epub ahead of print]

Panzer AR, Lynch SV, Langelier C, Christie JD, McCauley K, Nelson M, Cheung CK, Benowitz NL, Cohen MJ, Calfee CS.: Lung Microbiota Is Related to Smoking Status and to Development of Acute Respiratory Distress Syndrome in Critically Ill Trauma Patients. Am J Respir Crit Care Med March 2018.

Bime C, Pouladi N, Sammani S, Batai K, Casanova N, Zhou T, Kempf CL, Sun X, Camp SM, Wang T, Kittles RA, Lussier YA, Jones TK, Reilly JP, Meyer NJ, Christie JD, Karnes J, Gonzalez-Garay M, Christiani DC, Yates CR, Wurfel MM, Meduri GU, Garcia JGN.: Genome Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor. Am J Respir Crit Care Med February 2018 Notes: Epub ahead of print.

Negorev D, Beier UH, Zhang T, Quatromoni JG, Bhojnagarwala P, Albelda SM, Singhal S, Eruslanov E, Lohoff FW, Levine MH, Diamond JM, Christie JD, Hancock WW, Akimova T.: Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms. Sci Rep. 8(1): 3135, February 2018.

Anderson BJ, Chesley CF, Theodore M, Christie C, Tino R, Wysoczanski A, Ramphal K, Oyster M, Kalman L, Porteous MK, Bermudez CA, Cantu E, Kolson DL, Christie JD, Diamond JM.: Incidence, risk factors, and clinical implications of post-operative delirium in lung transplant recipients. J Heart Lung Transplant February 2018 Notes: Epub ahead of print

Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. Shaver CM, Wickersham N, McNeil JB, Nagata H, Miller A, Landstreet SR, Kuck JL, Diamond JM, Lederer DJ, Kawut SM, Palmer SM, Wille KM, Weinacker A, Lama VN, Crespo MM, Orens JB, Shah PD, Hage CA, Cantu E 3rd, Porteous MK, Dhillon G, McDyer J, Bastarache JA, Christie JD, Ware LB; Lung Transplant Outcomes Group (LTOG). : Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight January 2018 Notes: Epub ahead of print

Meyer NJ, Reilly JP, Anderson BJ, Palakshappa JA, Jones TK, Dunn TG, Shashaty MGS, Feng R, Christie JD, Opal SM.: Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration. Crit Care Med January 2018.

Courtwright AM, Zaleski D, Gardo L, Ahya VN, Christie JD, Crespo M, Hadjiliadis D, Lee J, Molina M, Patel N, Porteous M, Cantu EE, Bermudez C, Diamond JM.: Causes, Preventability, and Cost of Unplanned Rehospitalizations Within 30 Days of Discharge Following Lung Transplantation. Transplantation January 2018.

Diamond JM, Ramphal K, Porteous MK, Cantu E 3rd, Christie JD, Kawut SM; Lung Transplant Outcomes Group.: Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients. J Heart Lung Transplant December 2017 Notes: Epub ahead of print.

back to top
Last updated: 04/26/2018
The Trustees of the University of Pennsylvania